Navigation Links
Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
Date:10/14/2008

his FOB trial is the second of two planned for 2008 as part of Insmed's development of a portfolio of FOBs. In July 2008, the Company announced that a completed Phase I clinical trial had demonstrated the bioequivalence of INS-19, the Company's recombinant human granulocyte colony stimulating factor (G-CSF), compared to Neupogen(R), an FDA-approved G-CSF product for the treatment of neutropenia that recorded 2007 sales of approximately $1 billion. Insmed intends to seek approval of INS-19 and INS-20 in the U.S. and launch the products on expiration of the relevant innovator patents, which is in 2013 for Neupogen(R) and 2015 for Neulasta(R).

The Follow-on Biologics Market

According to published reports, an estimated $10 billion worth of biologic drugs are expected to come off patent by 2010, with an additional $10 billion by 2015. FOBs would provide safe and effective therapies at a reduced cost following the expiration of the original product's patent. A recent econometric study by economist Dr. Robert J. Shapiro, former Under Secretary of Commerce in the Clinton Administration, found that "...generic versions of the top 12 categories of biologic treatments with patent protections that have expired or that are due to expire in the near future could save Americans $67 billion to $108 billion over 10 years and $236 billion to $378 billion over 20 years."

About INS-20

Pegylated recombinant human G-CSF is a chemically modified version of G-CSF in which a water soluble polymer called polyethylene glycol is attached to the protein. The pegylated protein has a prolonged biological activity after it is injected into the patient. This allows less frequent dosing for the patient compared to recombinant human G-CSF. The FDA approved version of this drug is Neulasta(R). INS-20 is Insmed's follow-on biologic version of Neulasta(R).

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manuf
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
2. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
3. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
6. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
7. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
8. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
9. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
10. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... According to a new market research report "Blood ... Application (Aerobic, Anaerobic, Yeast/ Fungi) & End User (Hospital, Reference ... published by MarketsandMarkets, The global Blood Culture Tests Market is ... in 2014 at a CAGR of 7.2% from 2014-2019. ... ma rket data T ables and ...
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "The New ... report to their offering. The report, ... Market, provides unique insights into the current development ... global preclinical development outsourcing market. The report is ...
(Date:7/7/2015)... July 7, 2015 ... P&R annonce l,acquisition de 20% du Groupe ... mondial, spécialisée dans la fabrication de médicaments ... hyaluronique.      (Logo: http://photos.prnewswire.com/prnh/20150707/232398LOGO) , ... principaux groupes chimiques et pharmaceutiques italiens, qui ...
Breaking Medicine Technology:Blood Culture Tests Market Worth $3,893.5 Million by 2019 2Blood Culture Tests Market Worth $3,893.5 Million by 2019 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 4New Trends in the 2015 Global Preclinical Development Outsourcing Market 2New Trends in the 2015 Global Preclinical Development Outsourcing Market 3New Trends in the 2015 Global Preclinical Development Outsourcing Market 4New Trends in the 2015 Global Preclinical Development Outsourcing Market 5
... Laboratory (IL) today announced total worldwide sales in 2010 ... 11.5% growth v. previous year in current, and 10.3% ... segments, Critical Care and Hemostasis Diagnostics, worldwide growth in ... 9.7% (8.9% in local currencies), respectively.   ...
... 22, 2011 Later this month, Quest Diagnostics ... benefit from $39 billion in federal incentives by ... EHR Road Test tour was developed to help hospitals ... and financial benefits of electronic health records and Care360 EHR. ...
Cached Medicine Technology:Instrumentation Laboratory Achieves Record Sales in 2010 2Instrumentation Laboratory Achieves Record Sales in 2010 3Quest Diagnostics Launches National Electronic Health Records Awareness Tour Showcasing Care360 EHR 2Quest Diagnostics Launches National Electronic Health Records Awareness Tour Showcasing Care360 EHR 3
(Date:7/7/2015)... NY (PRWEB) , ... July 07, 2015 , ... Difass ... that can help pass those long, stressful days at work is knowing that there ... always as laid back and stress free as imagined. Planning for a vacation can ...
(Date:7/7/2015)... ... July 07, 2015 , ... The United States Centers ... Committee of Massachusetts , and the Multicultural AIDS Coalition $3.78 million for ... who have sex with men (MSM) and transgender women, the groups at highest ...
(Date:7/7/2015)... ... ... SC&H Group, a leading audit, tax, and consulting firm, recently hosted its ... company-wide volunteering efforts. , On an annual basis, in coordination with Business Volunteers ... throughout Baltimore and Washington D.C. , This year, SC&H Group’s team in ...
(Date:7/7/2015)... , ... July 07, 2015 , ... ... further enhance the experience for its patient community using its IDF ePHR, an ... patients with primary immunodeficiency diseases (PI) to easily track their health information, including ...
(Date:7/7/2015)... New York, NY (PRWEB) , ... July 07, 2015 , ... ... , a new convenient online destination for HSA holders. HSAstore.com makes it simple to ... List to help consumers better understand their accounts. , According to a ...
Breaking Medicine News(10 mins):Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 2Health News:Introducing HSAstore.com: A New E-commerce Site for Health Savings Account Eligible Products and Services 3
... tendon in the eye socket may help stop a migraine ... socket just before an attack starts.// The pain is due ... a condition known as trochleitis. A new study suggests that ... migraine itself. ,According to researchers in Texas, they ...
... appear to cut the risk of a heart attack ... bypass surgery, allows doctors to open clogged coronary arteries ... the narrowest point and inflating the balloon. But 3 ... will suffer a major setback within 4 years. Some ...
... defibrillators in people who have had heart attacks prevented sudden ... findings will likely lead to a dramatic and costly shift ... by adding a $20,000 defibrillator to the medicines now in ... the preventive use of these devices in people without apparent ...
... but it also prevents many other cancers through activating vitamin ... causes sunburn// - as a risk factor for melanoma, and ... not generally realised is that the reverse may also be ... Grant, an independent researcher based in Hopkins University has analysed ...
... antimicrobial properties of honey could prove effective in arresting ... dental caries, a New Zealand researcher will report at ... month. ,An enzyme in honey that produces hydrogen ... honey, according to Dr. Peter C. Molan, associate professor ...
... by taking a history of symptoms, a physical exam, ... rule out other causes, such as kidney disease.// Even ... blood test allows doctors to accurately find out whether ... congestive heart failure. ,This test is the most ...
Cached Medicine News:
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease)....
... The Trinity Biotech Captia™ ... Assay (ELISA) is intended for ... antibodies (IgG and IgM) to ... in serum from patients with ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: